| Report number | MED-036 |
| Title | Clinical and Pre-clinical Evaluation of Theranostic Pair (Terbium-161 and Terbium-155) for Imaging and Radionuclide Targeted Therapy of Tumors |
| Author(s) | Khan, Qaiser (PINSTECH) |
| Publication | 2023 |
| Imprint | 2023-12-01 |
| Number of pages | 3 |
| Keywords | MEDICIS ; 155Tb ; Theranostics ; Targetted radionuclide therapy ; isotope mass separation |
| Abstract | The idea of theranostic approach is rapidly gaining momentum among the academia and practitioners in nuclear medicine community and there is considerable interest to commercially produce these isotopes for clinical applications. The approach combines diagnosis and therapy with suitable radiotracers. One of the most promising theranostic pair comes from the quadruped of terbium isotopes e.g., Terbium-161 (quite often referred to as the Swiss knife of nuclear medicine) and Terbium-155. Reactor produced Terbium-161 emits beta particles for therapeutic applications while accelerator produced Terbium-155 emits gamma rays for SPECT diagnosis. Both of the isotopes have suitable comparable half-lives for therapy as well as imaging for the required extended period of time. Isotopes of the same element as theranostic pair offers excellent mapping due to the same biological pathways and distribution. Global capability of Tb-155 production is limited owing to limited numbers of high energy particle accelerators. PINSTECH and MEDICIS facility at CERN has already signed an active collaboration agreement in the field of novel theranostic isotopes production. As part of the collaboration, one PINSTECH scientist is deputed on secondment at MEDICIS for the radiochemistry experiments for one year. Three scientists from PINSTECH have already completed the assignment at CERN while the fourth one is currently in MEDICIS for the experimentation. Three consignments of Actinium-225, a promising alpha emitter for targeted radionuclide therapy, have been received at PINSTECH from MEDICIS. Radiolabelling of Ac-225 has successfully been demonstrated at INMOL-Lahore while the work on the Generator System for Ra-225/Ac-225 is currently underway at IPD-PINSTECH. Irradiation facility at PARR-1 is used for enriched Platinum-194 and the irradiated sample as Platinum-195m is shipped back to MEDICIS for clinical studies |
| Submitted by | thierry.stora@cern.ch |
记录创建於2023-12-03，最後更新在2023-12-03
